NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors

癌症研究 CD16 细胞 细胞毒性T细胞 细胞培养 酪氨酸激酶 免疫学 生物 细胞生物学 体外 CD8型 抗原 CD3型 信号转导 遗传学 生物化学
作者
Ha-Ram Park,Yong‐Oon Ahn,Tae Min Kim,Soyeon Kim,Seulki Kim,YU SOO LEE,MISO KIM,Bhumsuk Keam,Dong-Wan Kim,Dae Seog Heo
出处
期刊:Cytotherapy [Elsevier BV]
卷期号:21 (6): 603-611 被引量:20
标识
DOI:10.1016/j.jcyt.2019.03.312
摘要

Background Treatment with tyrosine kinase inhibitors (TKIs) has improved the outcomes for patients with non-small cell lung cancer (NSCLC) harboring targetable driver mutations. However, acquired resistance to TKIs invariably develops within approximately 1 year of treatment by various mechanisms, including gatekeeper mutations, alternative pathway activation and histological transformations. Because immunotherapy is an option for patients with drug-resistant cancers, we generated several TKI-resistant NSCLC cell lines in vitro, and then evaluated the cytotoxicity of NK92-CD16 cells to these resistant cells. Materials and Methods TKI-resistant NSCLC cells (H3122CR1, H3122LR1, H3122CR1LR1, PC-9GR, PC-9ER, EBC-CR1 and EBC-CR2) were established from NCI-H3122 (EML4-ALK fusion), PC-9 (EGFR exon19 deletion) and EBC-1 (MET amplification) after continuous exposure to crizotinib, ceritinib, gefitinib, erlotinib and capmatinib. Expression of ligands for natural killer (NK) cell receptors and total EGFR were analyzed using flow cytometry. NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) using anti-EGFR monoclonal antibody (mAb) cetuximab were measured using NK92-CD16 as effectors and detected using the 51Chromium-release assay. Results We found that NK92-CD16 cells preferentially killed TKI-resistant NSCLC cells when compared with their parental NSCLC cells. Mechanistically, intracellular adhesion molecule 1 (ICAM-1) was up-regulated in the TKI-resistant NSCLC cells and patients’ tumors, and the ICAM-1 up-regulated cancer cells lines were less susceptible to NK cytotoxicity by blocking ICAM-1. Moreover, NK92-CD16 cell-induced cytotoxicity toward TKI-resistant NSCLC cells was enhanced in the presence of cetuximab, an EGFR-targeting mAb. Conclusion These data suggest that combinational treatment with NK cell–based immunotherapy and cetuximab may be promising for patients with TKI-resistant NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
情怀应助xuanhui采纳,获得10
刚刚
yanmu2010完成签到,获得积分10
1秒前
单薄电源完成签到,获得积分10
1秒前
2秒前
2秒前
尉迟衣完成签到,获得积分10
3秒前
xmyyy完成签到,获得积分10
3秒前
暖暖发布了新的文献求助10
3秒前
香蕉觅云应助moyan采纳,获得10
4秒前
4秒前
852应助Jaaay采纳,获得10
4秒前
4秒前
黑凤梨发布了新的文献求助10
4秒前
wangfen发布了新的文献求助10
4秒前
小桃子完成签到 ,获得积分10
5秒前
羽言完成签到,获得积分10
5秒前
xmyyy发布了新的文献求助10
5秒前
HUHIUH完成签到,获得积分20
5秒前
热塑性哈士奇完成签到,获得积分10
6秒前
量子星尘发布了新的文献求助10
6秒前
冰魄落叶完成签到,获得积分10
7秒前
汉堡包应助屹男采纳,获得10
7秒前
8秒前
8秒前
qwe完成签到,获得积分10
8秒前
田様应助浩浩采纳,获得10
8秒前
今天也要开心Y完成签到,获得积分10
8秒前
9秒前
9秒前
hihi完成签到,获得积分10
9秒前
世界末末日完成签到 ,获得积分10
9秒前
thunder发布了新的文献求助10
9秒前
李爱国应助风清扬采纳,获得10
9秒前
科研通AI2S应助何事惊慌采纳,获得10
10秒前
无奈的博超完成签到,获得积分10
10秒前
顺利的中道完成签到,获得积分10
11秒前
zhangz完成签到,获得积分10
11秒前
早阿完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Einführung in die Rechtsphilosophie und Rechtstheorie der Gegenwart 1500
NMR in Plants and Soils: New Developments in Time-domain NMR and Imaging 600
Electrochemistry: Volume 17 600
经络辨证用药学 500
Physical Chemistry: How Chemistry Works 500
SOLUTIONS Adhesive restoration techniques restorative and integrated surgical procedures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4952800
求助须知:如何正确求助?哪些是违规求助? 4215536
关于积分的说明 13113791
捐赠科研通 3997480
什么是DOI,文献DOI怎么找? 2187918
邀请新用户注册赠送积分活动 1203086
关于科研通互助平台的介绍 1115874